ACR Appropriateness Criteria® Noninvasive Clinical Staging of Primary Lung Cancer
Publication date: May 2019Source: Journal of the American College of Radiology, Volume 16, Issue 5, SupplementAuthor(s): Expert Panel on Thoracic Imaging:, Patricia M. de Groot, Jonathan H. Chung, Jeanne B. Ackman, Mark F. Berry, Brett W. Carter, Patrick M. Colletti, Stephen B. Hobbs, Barbara L. McComb, Benjamin Movsas, Betty C. Tong, Christopher M. Walker, Sue S. Yom, Jeffrey P. KanneAbstractLung cancer is the leading cause of cancer-related deaths in both men and women. The major risk factor for lung cancer is personal tobacco smoking, particularly for small-cell lung cancer (SCLC) and squamous cell lung cancers, but other significant risk factors include exposure to secondhand smoke, environmental radon, occupational exposures, and air pollution. Education and socioeconomic status affect both incidence and outcomes. Non–small-cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, comprises about 85% of lung cancers. SCLC accounts for approximately 13% to 15% of cases. Prognosis is directly related to stage at presentation. NSCLC is staged using the eighth edition of the tumor-node-metastasis (TNM) criteria of the American Joint Committee on Cancer. For SCLC the eighth edition of TNM staging is recommended to be used in conjunction with the modified Veterans Administration Lung Study Group classification system distinguishing limited stage from extensive stage SCLC.The American College of Radiology Appropriateness Criter...
Conclusions: These results suggest that FGFR1 amplification occurs more frequently in SCC and in Asians. FGFR1 amplification may be a potential new therapeutic target for specific patients and lung cancer subtypes. PMID: 32051701 [PubMed]
The development of targeted therapies has revolutionized the treatment of patients with lung cancer, especially non-small-cell lung cancer (NSCLC). Anaplastic lymphoma kinase (ALK) is a research hotspot of molecular targeted therapy for lung cancer. ALK tyrosine kinase inhibitors (TKIs) are highly effective for ALK-rearranged NSCLC-positive patients. These targeted therapies have significant clinical effects; however, they inevitably lead to acquired resistance. In previous studies, the histological transformation after ALK inhibitor treatment was mostly based on small-cell lung cancer (SCLC).
Conclusion: These findings indicate that a majority of EBUS-TBNA specimens provide sufficient tissue for subtyping pulmonary NSCLC and SCLC while performing IHC.
Conclusions: The endosonography with use of histological 25G core needles is feasible and safe and seems to be a reasonable approach for IHC and MT in advanced LC patients
Conclusions: This study concludes that 68Ga Pentixafor is a promising future PET molecule for imaging CXCR4 over expression reported in lung cancer and many other human malignancies. This novel PET tracer has the potential of becoming a powerful tool for monitoring therapy response to CXCR4 inhibitors and also for the development of emerging alpha/beta targeted therapies in advanced stage lung carcinoma. $$graphic_078CAB3A-2C78-49E0-8A2E-0F11F0BF0518$$
Lung cancer is the leading cause of cancer related mortality globally and is classified as either Small Cell Lung Cancer (SCLC) or Non-Small Cell Lung Cancer (NSCLC) upon pathology review. [1,2] The main histologic types of NSCLC include squamous cell carcinoma and adenocarcinoma.  The majority of patients have non-curable disease stage at the time of diagnosis. Advances in systemic treatments including chemotherapy, targeted therapies and immune check point inhibitors have improved prognosis in recent years.
Lung cancer is the leading cause of cancer-related deaths in both men and women. The major risk factor for lung cancer is personal tobacco smoking, particularly for small-cell lung cancer (SCLC) and squamous cell lung cancers, but other significant risk factors include exposure to secondhand smoke, environmental radon, occupational exposures, and air pollution. Education and socioeconomic status affect both incidence and outcomes. Non –small-cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, comprises about 85% of lung cancers.
Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
This study evaluated its diagnostic value for differentiating between NSCLC and high-grade neuroendocrine tumor (HGNET).MethodsStathmin-1 protein expression was assessed by immunohistochemistry (IHC) in surgical specimens of 414 NSCLC (305 adenocarcinoma [AD], 102 squamous cell carcinoma [SCC], 7 large-cell carcinoma [LA]), 5 typical carcinoid (TC; a low-grade neuroendocrine tumor), and 34 HGNET (17 small-cell carcinoma [SCLC] and 17 large-cell neuroendocrine carcinoma [LCNEC]) and biopsy specimens of 57 NSCLCs (29 AD and 28 SCC) and 42 HGNETs (17 LCNEC and 25 SCLC). We also analyzed stathmin-1 mRNA levels in 81 NSCLC and ...
The soluble forms of PD-1 and PD-L1 (sPD-1, sPD-L1) were detected in the blood of patients (pts) with tumors. Evidence suggests that the blood levels of sPD-1/PD-L1 might facilitate the prediction of clinic/pathological characteristics, treatment response, and survival outcomes.Aim: to evaluate soluble sPD-L1 plasma concentrations in lung cancer (LC) pts, and their correlation with clinico-pathological characteristics and treatment response.Method: Plasma samples of 95 LC pts were examined for soluble PD-L1 blood concentration with DuoSet ELISA system.Results: M:F ratio 66:29 (69.5%:30.5%), median age of 64 years (range 30...
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Education | Environmental Health | Lung Cancer | Non-Small Cell Lung Cancer | Occupational Health | Radiology | Skin Cancer | Small Cell Lung Cancer | Smokers | Squamous Cell Carcinoma | Study | Universities & Medical Training | Women